Impurity Case Studies: Pharmacology/Toxicology (22of28) Generic Drugs Forum – Apr. 3-4, 2019
Автор: U.S. Food and Drug Administration
Загружено: 2020-03-26
Просмотров: 2010
CDER’s Office of Pharmaceutical Quality’s Hongbio Liao and Office of Generic Drugs’ Victoria Keck discuss impurities. A top RTR is due to impurity issues. Liao and Keck cover FDA adequate and inadequate impurity submissions. They also troubleshoot impurity challenges to include Potential Genotoxic Impurity (PGI) assessment in Type II DMFs as well as safety justifications for impurities exceeding International Conference on Harmonisation (ICH) limits in ANDAs.
Learn more at https://www.fda.gov/drugs/cder-small-...
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Visit https://www.fda.gov/cdersbia and https://www.fda.gov/cdersbialearn for news and a repository of training activities.
Email: CDERSBIA@fda.hhs.gov
Phone: (301) 796-6707 I (866) 405-5367
LinkedIn: / cder-small-business-and-industry-assistance
Twitter: / fda_drug_info
CDER small business e-mail update subscription: https://updates.fda.gov/subscriptionm...
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
